Study of D-2570 in Subjects With Non-Segmental Vitiligo

Summary

This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration. Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.

Timeline

Start

2026-06-11

Primary completion

2027-11

Completion

2028-05

Drugs

Indications